AB005. Acceptability of medication for early vascular ageing (EVA) in Malaysia: a focus group study
Haridah Alias1,2, Kit Mun Tan3, Hutkemri Zulnaidi4, Pooi Fong Wong5, Li Ping Wong2,6,7
Background: There has been extensive recent effort to identify potential drug candidates targeting cellular senescence to treat ageing-related comorbidities. In Malaysia, where cardiovascular diseases (CVDs) remain a major public health concern, such interventions may be especially valuable. Despite the growing relevance of early vascular ageing (EVA) in clinical research, little is known about how Malaysians perceive this concept or their views on the acceptability of related preventative medications. This qualitative study aimed to explore Malaysian young adults’ understanding of the concept of EVA, as well as their attitudes and acceptance of medication for EVA.
Methods: Six online focus group discussions (FGDs) were conducted with 31 Malaysian adults (aged 18–50 years) of diverse backgrounds between January and May 2024. Transcripts were analyzed thematically to explore perceptions, concerns, and acceptance of EVA medication.
Results: The awareness about EVA was low, although some participants had heard of known of premature death from sudden heart attacks among their friends or relatives. In general, older participants expressed higher perceived risk of EVA than the younger. Participants expressed concern over safety profile, long-term side effects, and efficiency of the medication. The acceptance of medication for EVA was moderate among younger participants and high among older participants. Some conditions that increase their acceptance were the physicians’ recommendation, convenient administration route, and affordable pricing.
Conclusions: Findings provide insights into the need to raise awareness about EVA, particularly among younger adults in Malaysia. Addressing concerns about medication safety and effectiveness, alongside clear guidance from healthcare providers, may enhance public acceptance. Interventions to reduce negative perceptions of new therapies and improve awareness about EVA may enhance acceptance of medication.
Keywords: Cardiovascular; focus group discussion (FGD); premature ageing; senotherapy; young adults
Footnote
Conflicts of Interest: The authors have no conflicts of interest to declare.
Cite this abstract as: Alias H, Tan KM, Zulnaidi H, Wong PF, Wong LP. AB005. Acceptability of medication for early vascular ageing (EVA) in Malaysia: a focus group study. J Public Health Emerg 2026;10:AB005.
